The original purpose of our study was to determine whether the regimen used by Arriagada and his collagues was Iogistically feasible in centres in the UK, whether the toxicity is acceptable, and whether a high complete response rate could be confirmed, with a view to then considering a multicentre randomised trial comparing alternating versus conventional scheduling. In the event, the working party concluded that the alternating regimen was logistilly feasible in only a small proportion of centres in the UK and that the level of toxicity was in excess of that tolerated by most patients. However, comparison of patients in the present study with patients with similar extent of disease and performance status, treated with conventionally scheduled chemotherapy and radiotherapy in a concurrent MRC triaL suggests that the long-term survival rates could be increased with intensive treatment.
They were all prescribed six cycles of chemotherapy, to be given during five consecutive days at 4 week intervals, and three courses of radiotherapy following the second, third and fourth cycles of chemotherapy.
The chemotherapy consisted of etoposide 75 mg m2 given by i.v. infusion on days 1, 2 and 3; doxorubicin 40 mg m-2 by i.v. injection on day 1; isplatin lOOmgm-2 by i.v. injection on day 2; and cyclophosphamide 300 mgm2 by i.v. injection on days 2, 3, 4 and 5. After 12 patients had been admitted, the cisplatin dosage was reduced to 80 mg m-2 because of excessive toxicity.
Radiotherapy was given using planned fields to all visible tumour with a 1.5 cm margin, as well as to the mediastinum, both lung hila and supraclavicular regions. It was given in fractions of 2 Gy five times per week; 20 Gy following the second and third cycles of chemotherapy and 15 Gy following the fourth cycle (total dose 55 Gy). The first two doses were given through opposed anteroposterior fields, the third through lateral fields avoiding the spinal cord.
The Kaplan-Meier estimate was used to caculate survival curves and the Mantel-Cox version of the log-rank test to make group comparisons. Survival was calculated from the date of start of chemotherapy.
Correspondence: Dr DJ. Girling, MRC Cancer Trials Office, 5 Shaftesbury Road, Cambridge CB2 2BW, UK. *Members: N.M. Beeben (Chairman until October 1989) , JJ. Long-term follow-up At the time of the previous report, only four patients had died. Since then, the patients have been followed up for an additional 3 years, during which time 14 more have died. The updated survival data are shown in Table I and Figure 1.  Table I Figure 2 , however, the same results are shown but with the patients divided according to their performance status. The survival curves (upper part of figure) for the 14 patients in the present study and the 163 in the conventionally treated group with a performance status of grade 1 or 2 are clearly very similar (hazard ratio 1.03; 95% confidence interval 0.59-1.80). In marked contrast, those for the eight patients from the present study and 52 from the conventionally treated group with a performance status of grade 0 strongly suggest that with the intensive alternating regimen the long-term survival rate was higher ( around 40% at 1 year, 30% at 2 years and 25% at 3 years can be achieved when patients with SCLC of limited extent and with good performance status are treated with an intensive regimen of alternating chemotherapy and radiotherapy. These findings confirm those of Arriagada and his colleagues, who reported a survival rate of 26% at 3 years in a study of 109 patients (Le Chevalier et al., 1987) , and of the Eastern Cooperative Oncology Group, which reported a progressionfree survival rate of 33% at 3 years in a study of 34 patients (Johnson et al., 1993) .
Nevertheless, none of these phase II studies provides conclusive evidence of the superiority of alternating over conventional scheduling. Indeed, these promising findings could be the result of patient selection. The European Organization for Research and Treatment of Cancer (EORTC) is currently conducting a randomised trial with a planned intake of 360 patients in which a regimen of cyclophosphamide, doxorubicin and etoposide plus thoracic radiotherapy is being given either with conventional sequential scheduling, the radiotherapy being given after completion of the five cycles of chemotherapy, or with alternating scheduling (protocol 08877). As far as we are aware, this is the only randomised trial that is making the important comparison of alternating vs conventional scheduling. The results are therefore awaited with great interest, although the chemotherapy is not as intensive as that used in this study. It is also desirable that other randomised trials investigate this comparison further.
In the present study, four of the patients died within 6 weeks of starting treatment, and treatment was considered a contributory cause of death in all four (Bleehen et al., 1991 Alternating chemotherapy and radiotherapy is logistically demanding and carries a substantial risk of major toxicity, but if it can offer even a small subgroup of patients a better chance of cure it may be worth the risk.
